Long title
A Phase I/II, multicenter study, evaluating the feasibility, safety, and efficacy of point-of-care manufactured 19CP02 in subjects with relapsed/refractory B-cell non-Hodglin lymphoma
Date receipt dossier
EU record number
CP0201-NHL
EudraCT number
2021-003272-13
Company / Sponsor
CellPoint B.V.
Phase
I/II
Treated organism
Humans
Indication category
Cancer therapy
Disease
Lymphomas non-Hodgkin's B-cell
Therapeutic approach
Immunotherapy
Genetic modification
CD19-CAR
Method of transfer of nucleic acid of interest
Lentiviral vector
Administered biological material
Autologous T-cells transduced with lentiviral vectors against CD19-CAR
Route of administration
Intravenous
Locations in Belgium
CHU de Liège, UZA
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
19CP02